<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853229</url>
  </required_header>
  <id_info>
    <org_study_id>CCF 08-195</org_study_id>
    <nct_id>NCT00853229</nct_id>
  </id_info>
  <brief_title>Pregabalin for the Treatment of Vulvodynia</brief_title>
  <official_title>Pregabalin (Lyrica) for the Treatment of Vulvodynia: A Randomized, Double-blinded, Placebo-controlled Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pregabalin is effective in the treatment of&#xD;
      vulvodynia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvodynia is a condition exclusive to women and involves mostly burning, rawness, and&#xD;
      itching of the external genitourinary tract that often results in painful intercourse.&#xD;
      Vulvodynia rarely results in severe morbidity or mortality; rather it causes symptoms of the&#xD;
      lower genital, urinary, and gastrointestinal tracts that can impact a woman's daily&#xD;
      activities and negatively affect her quality of life.&#xD;
&#xD;
      Despite the fact that chronic vulvovaginal symptoms are one of the most common reasons for&#xD;
      visits to a gynecology clinic, epidemiologic studies of the incidence and prevalence of these&#xD;
      conditions are rare and available population-based studies are limited. Approximately 16% of&#xD;
      women will experience chronic vulvar pain at some point in their lifetime; with 5%&#xD;
      experiencing this condition before age 25.&#xD;
&#xD;
      Treatment approaches include behavioral changes, medical management, and surgery,&#xD;
      specifically vulvar vestibulectomy. Prior to considering surgical intervention, all medical&#xD;
      treatment options should be exhausted. Although vulvodynia is quite prevalent and can be a&#xD;
      debilitating disease, there are few studies that critically evaluate the medical management&#xD;
      of vulvodynia. Pregabalin is an anticonvulsant that has proven efficacy in the treatment of&#xD;
      diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia. Anecdotal data and one case&#xD;
      report provide hope that this medication may also be effective in the treatment of&#xD;
      vulvodynia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not feasible due to low accrual&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Average Pain Over the Last 7 Days of Each Arm Using an 11-point Scale (0-10)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary objective of this protocol is to compare the reduction in pain using an 11-point scale (0-10) at four weeks of treatment. A responder will be defined as a subject noting a ≥50% reduction in pain using this scale.&#xD;
The NRS is an 11-point scale comprising a number from 0 through 10; 0 indicates &quot;no pain&quot;, and 10 indicates the &quot;worst imaginable pain&quot;.&#xD;
Outcomes measure not assessed due to early discontinuation because of poor recruitment. As such, the study was terminated prior to the designated follow up interval. Therefore, no outcomes data was collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Anxiety and Depression in Women With Vulvodynia Based on the Kessler Psychological Distress Scale (K10)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjects will complete the Kessler Psychological Distress Scale (K10). It is a measure of psychological distress. Scores will range from 10 to 50, with the higher the score, the higher the mental distress&#xD;
Data not measured due to early discontinuation of the study prior to the designated follow up time frame.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Vulvodynia</condition>
  <condition>Vulvar Vestibulitis</condition>
  <arm_group>
    <arm_group_label>pregabalin/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pregabalin and placebo given using a cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo/pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo and pregabalin given using a cross-over design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>pregabalin 150mg twice daily for 4 weeks</description>
    <arm_group_label>placebo/pregabalin</arm_group_label>
    <arm_group_label>pregabalin/placebo</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women age 18 or greater&#xD;
&#xD;
          -  Vulvodynia as defined as chronic vulvar discomfort or pain, characterized by burning,&#xD;
             stinging, irritation or rawness of the female genitalia in cases in which there is no&#xD;
             infection or skin disease of the vulva or vagina causing these symptoms. Pain may be&#xD;
             constant or intermittent, localized or diffuse. Symptoms may be consistent with either&#xD;
             Generalized Vulvodynia (diffuse or focal and constant or unremitting symptoms present&#xD;
             in the labia majora, labia minora, and/or the vestibule that are not necessarily&#xD;
             caused by touch or pressure to the vulva) or Vulvar Vestibulitis Syndrome (pain only&#xD;
             in the vestibule and only during or after touch or pressure is applied).&#xD;
&#xD;
          -  Pain ≥ 40 on 100mm VAS&#xD;
&#xD;
          -  Practicing reliable form of birth control defined as sterilization, hormonal&#xD;
             contraception, abstinence, IUD&#xD;
&#xD;
          -  Must be able to attend follow up visits and are not likely to leave the area during&#xD;
             the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrophic vaginitis, active bacterial vaginosis, yeast, and herpetic infections&#xD;
&#xD;
          -  Current pregnancy diagnosed by positive serum or urine pregnancy test&#xD;
&#xD;
          -  Current breastfeeding&#xD;
&#xD;
          -  Seizure disorder or other chronic neurologic disease&#xD;
&#xD;
          -  Diagnosis of chronic renal insufficiency defined as creatinine &gt;1.4&#xD;
&#xD;
          -  Unable to read and speak English&#xD;
&#xD;
          -  Contraindication to pregabalin or history of prior use of pregablin&#xD;
&#xD;
          -  Chronic narcotic or benzodiazepine use&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
          -  Other chronic pain disorders, (ie. chronic pelvic pain, endometriosis, interstitial&#xD;
             cystitis)&#xD;
&#xD;
          -  Chronic neuropathic pain or anything affecting sensation (ie. MS, stroke)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beri M Ridgeway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew D Barber, MD, MHS</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vulvodynia</keyword>
  <keyword>vulvar vestibulitis</keyword>
  <keyword>chronic vulvar pain</keyword>
  <keyword>generalized vulvodynia</keyword>
  <keyword>localized vulvodynia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvodynia</mesh_term>
    <mesh_term>Vulvar Vestibulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin First 4 Weeks</title>
          <description>pregabalin and placebo given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First 4 Weeks</title>
          <description>placebo and pregabalin given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: Initial Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early study termination, poor enrollment</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2: Cross Over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No study analysis completed due to early termination due to poor enrollment</population>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin First 4 Weeks</title>
          <description>pregabalin and placebo given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo First 4 Weeks</title>
          <description>placebo and pregabalin given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="8.9"/>
                    <measurement group_id="B2" value="36.3" spread="13.1"/>
                    <measurement group_id="B3" value="35.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Average Pain Over the Last 7 Days of Each Arm Using an 11-point Scale (0-10)</title>
        <description>The primary objective of this protocol is to compare the reduction in pain using an 11-point scale (0-10) at four weeks of treatment. A responder will be defined as a subject noting a ≥50% reduction in pain using this scale.&#xD;
The NRS is an 11-point scale comprising a number from 0 through 10; 0 indicates &quot;no pain&quot;, and 10 indicates the &quot;worst imaginable pain&quot;.&#xD;
Outcomes measure not assessed due to early discontinuation because of poor recruitment. As such, the study was terminated prior to the designated follow up interval. Therefore, no outcomes data was collected.</description>
        <time_frame>4 weeks</time_frame>
        <population>Outcomes measure not assessed due to early discontinuation because of poor recruitment. As such, the study was terminated prior to the designated follow up interval. Therefore, no outcomes data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin/Placebo</title>
            <description>pregabalin and placebo given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Pregabalin</title>
            <description>placebo and pregabalin given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Average Pain Over the Last 7 Days of Each Arm Using an 11-point Scale (0-10)</title>
          <description>The primary objective of this protocol is to compare the reduction in pain using an 11-point scale (0-10) at four weeks of treatment. A responder will be defined as a subject noting a ≥50% reduction in pain using this scale.&#xD;
The NRS is an 11-point scale comprising a number from 0 through 10; 0 indicates &quot;no pain&quot;, and 10 indicates the &quot;worst imaginable pain&quot;.&#xD;
Outcomes measure not assessed due to early discontinuation because of poor recruitment. As such, the study was terminated prior to the designated follow up interval. Therefore, no outcomes data was collected.</description>
          <population>Outcomes measure not assessed due to early discontinuation because of poor recruitment. As such, the study was terminated prior to the designated follow up interval. Therefore, no outcomes data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Anxiety and Depression in Women With Vulvodynia Based on the Kessler Psychological Distress Scale (K10)</title>
        <description>Subjects will complete the Kessler Psychological Distress Scale (K10). It is a measure of psychological distress. Scores will range from 10 to 50, with the higher the score, the higher the mental distress&#xD;
Data not measured due to early discontinuation of the study prior to the designated follow up time frame.</description>
        <time_frame>4 weeks</time_frame>
        <population>Data not measured due to early discontinuation of the study prior to the designated follow up time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin First 4 Weeks</title>
            <description>pregabalin and placebo given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo First 4 Weeks</title>
            <description>placebo and pregabalin given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Anxiety and Depression in Women With Vulvodynia Based on the Kessler Psychological Distress Scale (K10)</title>
          <description>Subjects will complete the Kessler Psychological Distress Scale (K10). It is a measure of psychological distress. Scores will range from 10 to 50, with the higher the score, the higher the mental distress&#xD;
Data not measured due to early discontinuation of the study prior to the designated follow up time frame.</description>
          <population>Data not measured due to early discontinuation of the study prior to the designated follow up time frame.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Data not collected. Long term follow up not available for adverse events as study was discontinued early.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin/Placebo</title>
          <description>pregabalin and placebo given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Pregabalin</title>
          <description>placebo and pregabalin given using a cross-over design&#xD;
pregabalin: pregabalin 150mg twice daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Borzi (Research Administrator)</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-3158</phone>
      <email>BORZIL@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

